Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the ...

Farabursen is being developed as a treatment for autosomal dominant polycystic kidney disease (ADPKD). This rare disease leads to the development of cysts in organs, mainly the kidneys.

But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic ...

Ms Milanova, now 30, got her first period at just nine but, without any education about menstruation, feared she was gravely ...

Despite the diagnosis, Valentina continued to grapple with cysts, severe pain, bloating, and heavy bleeding. Her personal ...